Phase I/II Evaluation of the Immune Checkpoint Inhibitor, Pembrolizumab in Combination With Oral Decitabine and Tetrahydrouridine as First-Line Therapy for Inoperable, or Unresectable Locally Advanced or Metastatic Non-small Cell Lung Cancer

Trial Profile

Phase I/II Evaluation of the Immune Checkpoint Inhibitor, Pembrolizumab in Combination With Oral Decitabine and Tetrahydrouridine as First-Line Therapy for Inoperable, or Unresectable Locally Advanced or Metastatic Non-small Cell Lung Cancer

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 18 Jul 2018

At a glance

  • Drugs Decitabine (Primary) ; Pembrolizumab (Primary) ; Tetrahydrouridine (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 11 Jul 2018 Planned End Date changed from 15 Apr 2020 to 31 Dec 2020.
    • 11 Jul 2018 Planned primary completion date changed from 1 Dec 2018 to 31 Dec 2019.
    • 13 Apr 2018 Planned initiation date changed from 5 Apr 2018 to 18 Apr 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top